 Connection
Scot Sedlacek to Adult
This is a "connection" page, showing publications Scot Sedlacek has written about Adult.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.070 |
|
|
|
-
Jones VE, McIntyre KJ, Paul D, Wilks ST, Ondreyco SM, Sedlacek S, Melnyk A, Oommen SP, Wang Y, Peck SR, O'Shaughnessy JA. Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study. Oncologist. 2019 09; 24(9):1153-1158.
Score: 0.007
-
Osborne C, Challagalla JD, Eisenbeis CF, Holmes FA, Neubauer MA, Koutrelakos NW, Taboada CA, Vukelja SJ, Wilks ST, Allison MA, Reddy P, Sedlacek S, Wang Y, Asmar L, O'Shaughnessy J. Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer. Clin Breast Cancer. 2018 02; 18(1):e89-e95.
Score: 0.006
-
Leonard CE, Wood ME, Zhen B, Rankin J, Waitz DA, Norton L, Howell K, Sedlacek S. Does administration of chemotherapy before radiotherapy in breast cancer patients treated with conservative surgery negatively impact local control? J Clin Oncol. 1995 Dec; 13(12):2906-15.
Score: 0.006
-
O'Shaughnessy J, Koeppen H, Xiao Y, Lackner MR, Paul D, Stokoe C, Pippen J, Krekow L, Holmes FA, Vukelja S, Lindquist D, Sedlacek S, Rivera R, Brooks R, McIntyre K, Brownstein C, Hoersch S, Blum JL, Jones S. Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. Clin Cancer Res. 2015 Oct 01; 21(19):4305-11.
Score: 0.005
-
Jones SE, Collea R, Paul D, Sedlacek S, Favret AM, Gore I, Lindquist DL, Holmes FA, Allison MAK, Brooks BD, Portillo RM, Vukelja SJ, Steinberg MS, Stokoe C, Crockett MW, Wang Y, Asmar L, Robert NJ, O'Shaughnessy J. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol. 2013 Oct; 14(11):1121-1128.
Score: 0.005
-
Sedlacek SM. First-line and salvage therapy of metastatic breast cancer with mitomycin/vinblastine. Oncology. 1993 Apr; 50 Suppl 1:16-21.
Score: 0.005
-
Marcus AC, Garrett KM, Cella D, Wenzel L, Brady MJ, Fairclough D, Pate-Willig M, Barnes D, Emsbo SP, Kluhsman BC, Crane L, Sedlacek S, Flynn PJ. Can telephone counseling post-treatment improve psychosocial outcomes among early stage breast cancer survivors? Psychooncology. 2010 Sep; 19(9):923-32.
Score: 0.004
-
Sedlacek SM. Salvage therapy for metastatic disease. Semin Oncol. 1990 Aug; 17(4 Suppl 7):45-9.
Score: 0.004
-
Loesch D, Greco FA, Senzer NN, Burris HA, Hainsworth JD, Jones S, Vukelja SJ, Sandbach J, Holmes F, Sedlacek S, Pippen J, Lindquist D, McIntyre K, Blum JL, Modiano MR, Boehm KA, Zhan F, Asmar L, Robert N. Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer. J Clin Oncol. 2010 Jun 20; 28(18):2958-65.
Score: 0.004
-
Leonard CE, Tallhamer M, Johnson T, Hunter K, Howell K, Kercher J, Widener J, Kaske T, Paul D, Sedlacek S, Carter DL. Clinical experience with image-guided radiotherapy in an accelerated partial breast intensity-modulated radiotherapy protocol. Int J Radiat Oncol Biol Phys. 2010 Feb 01; 76(2):528-34.
Score: 0.004
-
Osborne CR, Duncan A, Sedlacek S, Paul D, Holmes F, Vukelja S, Kasper M, Wilks S, Schneider A, McGee R, Meyer WG, O'Shaughnessy JA. The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer. Breast Cancer Res Treat. 2009 Aug; 116(3):521-7.
Score: 0.004
-
Reeder R, Carter DL, Howell K, Henkenberns P, Tallhamer M, Johnson T, Kercher J, Widner J, Kaske T, Paul D, Sedlacek S, Leonard CE. Predictors for clinical outcomes after accelerated partial breast intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2009 May 01; 74(1):92-7.
Score: 0.003
-
Thompson HJ, Heimendinger J, Sedlacek S, Haegele A, Diker A, O'Neill C, Meinecke B, Wolfe P, Zhu Z, Jiang W. 8-Isoprostane F2alpha excretion is reduced in women by increased vegetable and fruit intake. Am J Clin Nutr. 2005 Oct; 82(4):768-76.
Score: 0.003
-
Thompson HJ, Heimendinger J, Gillette C, Sedlacek SM, Haegele A, O'neill C, Wolfe P. In vivo investigation of changes in biomarkers of oxidative stress induced by plant food rich diets. J Agric Food Chem. 2005 Jul 27; 53(15):6126-32.
Score: 0.003
-
Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005 Jun 01; 23(16):3686-96.
Score: 0.003
-
Haegele AD, Gillette C, O'Neill C, Wolfe P, Heimendinger J, Sedlacek S, Thompson HJ. Plasma xanthophyll carotenoids correlate inversely with indices of oxidative DNA damage and lipid peroxidation. Cancer Epidemiol Biomarkers Prev. 2000 Apr; 9(4):421-5.
Score: 0.002
-
Thompson HJ, Heimendinger J, Haegele A, Sedlacek SM, Gillette C, O'Neill C, Wolfe P, Conry C. Effect of increased vegetable and fruit consumption on markers of oxidative cellular damage. Carcinogenesis. 1999 Dec; 20(12):2261-6.
Score: 0.002
-
Bedell MB, Wood ME, Lezotte DC, Sedlacek SM, Orleans MM. Delay in diagnosis and treatment of breast cancer: implications for education. J Cancer Educ. 1995; 10(4):223-8.
Score: 0.001
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|